Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFN<i>α</i>-2a in Patients with Chronic Hepatitis B and the Associated Mechanism

<table class="table-group" id="tab3"><tr><td><table class="table"><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr class="thead"><td class="align_left">Feature</td><td class="align_center">Total cases</td><td class="align_center">F1</td><td class="align_center">F2</td><td class="align_center">≥F3</td><td class="align_center">Spearman’s rank correlation analysis</td><td class="align_center">Coefficient of contingency</td></tr><tr><td class="thead-hr" colspan="7"><hr/></td></tr><tr><td class="align_left">S0</td><td class="align_center">119</td><td class="align_center">69</td><td class="align_center">40</td><td class="align_center">10</td><td class="align_center" rowspan="4">0.202</td><td class="align_center" rowspan="4">-0.085</td></tr><tr><td class="align_left">S1</td><td class="align_center">76</td><td class="align_center">50</td><td class="align_center">20</td><td class="align_center">6</td></tr><tr><td class="align_left">S2</td><td class="align_center">22</td><td class="align_center">2</td><td class="align_center">6</td><td class="align_center">14</td></tr><tr><td class="align_left">S3</td><td class="align_center">9</td><td class="align_center">7</td><td class="align_center">2</td><td class="align_center">0</td></tr><tr class="table-tr"><td colspan="7"><hr class="tbody-hr"/></td></tr></table></td></tr></table>

<div>The correlation between baseline hepatic fibrosis stage and baseline hepatic steatosis degree.</div>

Gastroenterology Research and Practice

tab3

Table 3

Table 3: Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFN<i>α</i>-2a in Patients with Chronic Hepatitis B and the Associated Mechanism 

Gastroenterology Research and Practice

Impact of Hepatic Steatosis on the Antiviral Effects of PEG-IFNα-2a in Patients with Chronic Hepatitis B and the Associated Mechanism

Table 3